Skip to main content

Edwards Lifesciences Corp company profile

  • EW · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$107.11−0.04%Close 16 Nov 2026 · Market value $61.54B

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation develops and sells medical technologies for treating structural heart disease, with a focus on heart valves. Its portfolio spans transcatheter therapies and surgical products for the aortic, mitral, tricuspid and pulmonic valves. Product groups include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company sells primarily to hospitals, cardiac surgeons and interventional cardiologists, through direct sales forces and independent distributors. In 2025, 58% of net sales were in the United States and 42% outside it, with sales in approximately 100 countries. Manufacturing facilities are located in the United States, Singapore, Costa Rica and Ireland.

A summary of the business section of the company's latest annual report, filed 25 Feb 2026.

Company facts

TickerEW · NYSE
SectorMedical devices
IndustryHealth Care Equipment
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK1099800
Latest annual report10-K, filed 25 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
Dahl Andrew M.SVP, Corporate Controller—Shares withheld for tax, 13 Nov 2026
Lippis Daniel J.CVP, TAVR—Option exercise, 10 Nov 2026
Zovighian Bernard JCEO · Director—Option exercise, 9 Nov 2026
BOBO DONALD E JRCVP,Strategy/Corp Development—Option exercise, 9 Nov 2026
Markowitz WayneCVP, JAPAC—Shares withheld for tax, 14 Sep 2026
Chopra DaveenCVP, TMTT, Surgical & IHFM—Shares withheld for tax, 11 Sep 2026
Bruls AnnetteCVP, EMEACLA—Open-market sale, 28 Aug 2026
Mistras TheodoraCVP, Chief Financial Officer—Grant or award, 9 Jul 2026
Ullem Scott B.CVP, Chief Financial Officer—Option exercise, 11 May 2026
VALERIANI NICHOLAS JDirector—Grant or award, 8 May 2026
Sequeira RamonaDirector—Grant or award, 8 May 2026
LORANGER STEVEN RDirector—Grant or award, 8 May 2026
LAVIOLETTE PAUL ADirector—Grant or award, 8 May 2026
STONE HEISZ LESLIEDirector—Grant or award, 8 May 2026
GALLAHUE KIERANDirector—Grant or award, 8 May 2026
Feinberg David TDirector—Grant or award, 8 May 2026
Davis Leslie C.Director—Grant or award, 8 May 2026
Wood Larry LGlobal President TAVR & Surg—Option exercise, 18 Aug 2025

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

EW in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.